Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AIC100 |
Synonyms | |
Therapy Description |
AIC100 is a cell therapy consisting of T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the intercellular adhesion molecule-1 (ICAM-1), and CD28, potentially leading to activation of inhibitory T cells, inhibition of cell proliferation and inhibition of tumor growth (PMID: 31337787, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AIC100 | AIC-100|AIC 100 | AIC100 is a cell therapy consisting of T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the intercellular adhesion molecule-1 (ICAM-1), and CD28, potentially leading to activation of inhibitory T cells, inhibition of cell proliferation and inhibition of tumor growth (PMID: 31337787, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04420754 | Phase I | AIC100 | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | Recruiting | USA | 0 |